Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis

Molecular Metabolism

Volumn 6, Issue 3, 2017, Pages 267-275

  Holland, William L ^a   Xia, Jonathan Y ^a   Johnson, Joshua A ^a   Sun, Kai ^b   Pearson, Mackenzie J ^a   Sharma, Ankit X ^a   Quittner Strom, Ezekiel ^a   Tippetts, Trevor S ^a   Gordillo, Ruth ^a   Scherer, Philipp E ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Insulin resistance; NAFLD; Sphingolipid

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ADIPORON; CERAMIDASE; CYTOKINE RECEPTOR AGONIST; DOXYCYCLINE; GLUCOSE; INSULIN; SPHINGOSINE 1 PHOSPHATE; TETRACYCLINE; UNCLASSIFIED DRUG; ADIPONECTIN; ADIPONECTIN RECEPTOR; LEPTIN; LIPID; PIPERIDINE DERIVATIVE;

ADIPOCYTE; ADIPOR1 GENE; ADIPOR2 GENE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; FATTY LIVER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC MODEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID HOMEOSTASIS; LIVER CELL; LIVER LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HOMEOSTASIS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLISM; PHYSIOLOGY;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; CERAMIDASES; FATTY LIVER; GLUCOSE; HEPATOCYTES; HOMEOSTASIS; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPID METABOLISM; LIPIDS; LIVER; MICE; MICE, TRANSGENIC; PIPERIDINES; RECEPTORS, ADIPONECTIN;

EID: 85010993660     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2017.01.002     Document Type: Article

References (37)

1. [1] Asano, T., Watanabe, K., Kubota, N., Gunji, T., Omata, M., Kadowaki, T., et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. Journal of Gastroenterology and Hepatology 24:10 (2009), 1669–1676.
2. [2] Asterholm, I.W., Scherer, P.E., Enhanced metabolic flexibility associated with elevated adiponectin levels. American Journal of Pathology 176:3 (2010), 1364–1376.
3. [3] Halberg, N., Schraw, T.D., Wang, Z.V., Kim, J.Y., Yi, J., Hamilton, M.P., et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58:9 (2009), 1961–1970.
4. [4] Holland, W.L., Adams, A.C., Brozinick, J.T., Bui, H.H., Miyauchi, Y., Kusminski, C.M., et al. An FGF21-adiponectin-ceramide Axis controls energy expenditure and insulin action in mice. Cell Metabolism 17:5 (2013), 790–797.
5. [5] Holland, W.L., Brozinick, J.T., Wang, L.P., Hawkins, E.D., Sargent, K.M., Liu, Y., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metabolism 5:3 (2007), 167–179.
6. [6] Holland, W.L., Miller, R.A., Wang, Z.V., Sun, K., Barth, B.M., Bui, H.H., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nature Medicine 17:1 (2011), 55–63.
7. [7] Holland, W.L., Summers, S.A., Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocrine Reviews 29:4 (2008), 381–402.
8. [8] Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 464:7293 (2010), 1313–1319.
9. [9] Kim, J.Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M.E., Hofmann, S.M., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. The Journal of Clinical Investigation 117:9 (2007), 2621–2637.
10. [10] Kotronen, A., Yki-Jarvinen, H., Aminoff, A., Bergholm, R., Pietilainen, K.H., Westerbacka, J., et al. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. European Journal of Endocrinology 160:4 (2009), 593–602.
11. [11] Kupchak, B.R., Garitaonandia, I., Villa, N.Y., Smith, J.L., Lyons, T.J., Antagonism of human adiponectin receptors and their membrane progesterone receptor paralogs by TNFalpha and a ceramidase inhibitor. Biochemistry 48:24 (2009), 5504–5506.
12. [12] Kusminski, C.M., Holland, W.L., Sun, K., Park, J., Spurgin, S.B., Lin, Y., et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nature Medicine 18:10 (2012), 1539–1549.
13. [13] Levine, Y.C., Li, G.K., Michel, T., Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK -> Rac1 -> Akt -> endothelial nitric-oxide synthase pathway. Journal of Biological Chemistry 282:28 (2007), 20351–20364.
14. [14] Liu, Q., Yuan, B., Lo, K.A., Patterson, H.C., Sun, Y., Lodish, H.F., Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proceedings of the National Academy of Sciences of the United States of America 109:36 (2012), 14568–14573.
15. [15] Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:4 (2001), 402–408.
16. [16] Namvaran, F., Rahimi-Moghaddam, P., Azarpira, N., Nikeghbalian, S., The association between adiponectin (+45T/G) and adiponectin receptor-2 (+795G/A) single nucleotide polymorphisms with cirrhosis in Iranian population. Molecular Biology Reports 39:3 (2012), 3219–3223.
17. [17] Nawrocki, A.R., Rajala, M.W., Tomas, E., Pajvani, U.B., Saha, A.K., Trumbauer, M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. Journal of Biological Chemistry 281:5 (2006), 2654–2660.
18. [18] Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K., Matsuda, K., et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:7477 (2013), 493–499.
19. [19] Qiao, L., Kinney, B., Schaack, J., Shao, J., Adiponectin inhibits lipolysis in mouse adipocytes. Diabetes 60:5 (2011), 1519–1527.
20. [20] Raichur, S., Wang, S.T., Chan, P.W., Li, Y., Ching, J., Chaurasia, B., et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metabolism 20:4 (2014), 687–695.
21. [21] Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., Lodish, H.F., A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry 270:45 (1995), 26746–26749.
22. [22] Spiegel, S., Milstien, S., Sphingosine-1-phosphate: an enigmatic signalling lipid. Nature Reviews Molecular Cell Biology 4:5 (2003), 397–407.
23. [23] Sun, K., Wernstedt Asterholm, I., Kusminski, C.M., Bueno, A.C., Wang, Z.V., Pollard, J.W., et al. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proceedings of the National Academy of Sciences 109:15 (2012), 5874–5879.
24. [24] Stefan, N., Machicao, F., Staiger, H., Machann, J., Schick, F., Tschritter, O., et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48:11 (2005), 2282–2291.
25. [25] Takabe, K., Paugh, S.W., Milstien, S., Spiegel, S., “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacological Reviews 60:2 (2008), 181–195.
26. [26] Tsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. Journal of Biological Chemistry 279:29 (2004), 30817–30822.
27. [27] Turer, A.T., Browning, J.D., Ayers, C.R., Das, S.R., Khera, A., Vega, G.L., et al. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study. Journal of Clinical Endocrinology and Metabolism 97:6 (2012), E982–E986.
28. [28] Turpin, S.M., Nicholls, H.T., Willmes, D.M., Mourier, A., Brodesser, S., Wunderlich, C.M., et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metabolism 20:4 (2014), 678–686.
29. [29] Villa, N.Y., Kupchak, B.R., Garitaonandia, I., Smith, J.L., Alonso, E., Alford, C., et al. Sphingolipids function as downstream effectors of a fungal PAQR. Molecular Pharmacology 75:4 (2009), 866–875.
30. [30] Xia, J.Y., Holland, W.L., Kusminski, C.M., Sun, K., Sharma, A.X., Pearson, M.J., et al. Targeted induction of ceramide degradation reveals roles for ceramides in non alcoholic fatty liver disase and glucose metabolism in mice. Cell Metabolism 22:2 (2015), 266–278.
31. [31] Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S., Cooper, G.J., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. The Journal of Clinical Investigation 112:1 (2003), 91–100.
32. [32] Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S.L., Cooper, G.J.S., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. The Journal of Clinical Investigation 112:1 (2003), 91–100.
33. [33] Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:6941 (2003), 762–769.
34. [34] Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7:8 (2001), 941–946.
35. [35] Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nature Medicine 13:3 (2007), 332–339.
36. [36] Yano, W., Kubota, N., Itoh, S., Kubota, T., Awazawa, M., Moroi, M., et al. Molecular mechanism of moderate insulin resistance in adiponectin-knockout mice. Endocrine Journal 55:3 (2008), 515–522.
37. [37] Ye, R., Holland, W.L., Gordillo, R., Wang, M., Wang, Q.A., Shao, M., et al. Adiponectin is essential for lipid homeostasis and survival under insulin deficiency and promotes beta-cell regeneration. Elife, 3, 2014.